CO43805: A Phase 1b trial of mosunetuzumab or glofitamab in people with B-cell Non-Hodgkin Lymphoma

This trial is testing mosunetuzumab or glofitamab in combination with CC-220 or CC-99282 in people with B-cell non-Hodgkin lymphoma (B-cell NHL). 

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT05169515

Trial aim and background  

The aim of this trial is to find out how well mosunetuzumab or glofitamab works for people with B-cell NHL when given in combination with medications called CC-220 or CC-99282. It will also look at the impact on the body and any potential side effects. 

This is a phase 1 (early phase) trial. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment, but the trial will give important information about this new treatment, which could help other people in the future.

Who can enter

Anyone over 18 with relapsed or refractory B cell NHL who have previously received at least one systemic therapies may be eligible to apply.

Locations

Recruitment is taking place in the following UK locations:

  • University College London Hospitals, London
  • Nottingham University Hospitals City Campus, Nottingham
  • Oxford University Hospitals NHS Trust, Oxford

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/ct2/show/NCT05169515

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.